Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Legal Skirmishes Erupt as AstraZeneca Delves into Battle Over Drug Pricing Reforms with IRA
As the clock ticks down to the eagerly awaited unveiling of the Centers for Medicare and Medicaid Services’ (CMS) list ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
EC Approves Pfizer’s Abrysvo, Only RSV vaccine in EU for adults and infants
Pfizer has just received approval from the European Commission (EC) for its groundbreaking vaccine, Abrysvo. This vaccine, targeting the respiratory ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Akebia plans to resubmit vadadustat to FDA after rejection
After facing significant setbacks, including disappointment, a partnership setback, and an FDA dispute, Akebia Therapeutics has regrouped and is poised ...
Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy
Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Dräger Faces FDA Class I Recall on Carina Ventilators Due to Contaminant Concerns
Dräger, a German medical device manufacturer, is grappling with its fourth Class I recall by the FDA this year, this ...
Pfizer’s Approach to GBS Vaccine Approval Hinges on Immunogenicity Study
Amid the complexities of conducting an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer’s lead vaccine executive is ...
Amgen challenges FTC’s bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
FDA Advisors Favor Otsuka’s ReCor and Express Reservations on Medtronic’s Renal Denervation Therapies
During a two-day-long FDA meeting, a panel of advisors deliberated over competing proposals for novel renal denervation therapies, ultimately granting ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
Cellares Announces $255M Investment Round with Bristol Myers Squibb Among Key Investors
Cellares, a pioneering cell therapy manufacturer based in South San Francisco, has introduced a unique concept in the industry with ...
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
Following $1.7B Opioid Settlement, Mallinckrodt Prepares for Second Round of Bankruptcy Proceedings
In a recent development, Mallinckrodt has formally announced its decision to initiate another round of bankruptcy proceedings, marking its second ...
Agenus Shifts Focus to CTLA-4/PD-1 Combo Treatment, Implementing Layoffs and Pipeline Refinement
Agenus, an immuno-oncology firm, is reshaping its strategy to prioritize its CTLA-4/PD-1 combo treatment while temporarily redirecting its unpartnered programs. ...
Novartis Announces New Round of Layoffs at US Headquarters Following Earlier Job Cuts
Novartis, a Swiss pharmaceutical giant, is set to undergo another round of job cuts at its U.S. headquarters in East ...
Boehringer Ingelheim Enters Legal Fray Against Inflation Reduction Act, Citing Constitutional Concerns
The legal battle surrounding the Inflation Reduction Act (IRA) has intensified as pharmaceutical giant Boehringer Ingelheim joins the ranks of ...
FDA Rebukes Exeltis Over Misleading Social Media Post for Birth Control Pill Slynd
Exeltis, a pharmaceutical company, has come under sharp criticism from the FDA for a sponsored social media post promoting its ...
Novo Nordisk Turns to Thermo Fisher for Production Aid with Obesity Drug Wegovy Amid Catalent Challenges
Novo Nordisk Struggles to Keep Up with High Demand for Wegovy, Enlists Thermo Fisher to Boost Production Amid soaring demand ...
Gilead’s $100M COMPASS Initiative Shifts Course of the HIV Epidemic
Gilead Sciences is pausing to reflect on its $100 million commitment to combat the HIV/AIDS crisis in the southern United ...
Apellis Investigates Needle Issues Amid Search for Syfovre’s Side Effect Origins
Apellis, a pharmaceutical company, is zeroing in on a possible source of a rare but severe side effect associated with ...
Shingrix Maintains Perfect Score in GSK’s Shingles Vaccine Trial in China
In October of the previous year, GlaxoSmithKline (GSK) unveiled an ambitious strategy to double its presence in the Chinese market ...
Eli Lilly Sets Example for Roche with Positive Retevmo Results in Thyroid Cancer, Highlighting Feasibility of Trial
Just a few weeks ago, Roche had expressed doubts about the feasibility of a Phase 3 study involving its RET ...
Pfizer’s Abrysvo Achieves Landmark as First Maternal RSV Vaccine to Safeguard Newborns
Pfizer’s Abrysvo has achieved a groundbreaking milestone by becoming the first vaccine to safeguard newborns against respiratory syncytial virus (RSV) ...
Teva and Glenmark Agree to $255M Settlement with DOJ in Price-Fixing Case
Teva and Glenmark Pharmaceuticals, implicated in a price-fixing scheme, are facing substantial penalties and divestiture mandates after reaching a deferred ...
Medtronic’s Layoffs Earlier This Year Propel Broad-Based Revenue Growth
Medtronic Commences FY2024 with Encouraging Single-Digit Sales Growth Across Divisions Following Strategic Cost Reduction Measures Medtronic, a prominent player in ...
